Paper Details

  1. Home
  2. Paper Details

Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.

Author: BergPaul H, DennehyEllen B, DotyErin Gautier, HochstetlerHelen M, KhannaRashna, ShapiroRobert E, StarlingAmaal J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Lasmiditan, a selective serotonin 5-hydroxytryptamine 1F receptor agonist, is being evaluated for its safety and efficacy in acute treatment of migraine attacks in patients with CVRFs.
Paper Details　
Original Abstract of the Article :
In addition to the increased risk for cardiovascular (CV) disease and CV events associated with migraine, patients with migraine can also present with a number of CV risk factors (CVRFs). Existing treatment options can be limited due to contraindications, increased burden associated with monitoring,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734241/

データ提供：米国国立医学図書館（NLM）

Migraine and Cardiovascular Risk: A Desert of Complexities

Migraine is a painful and debilitating condition, like navigating a desert of intense headaches. This research explores the use of lasmiditan, a new medication, for treating acute migraine attacks in patients with cardiovascular risk factors. It's a quest for a safe and effective treatment in a landscape where medications often come with limitations.

Lasmiditan: A Beacon of Hope in the Desert

The researchers found that lasmiditan was effective and well-tolerated in patients with cardiovascular risk factors. This is like finding a reliable caravan route through a treacherous desert, offering a safe passage for those seeking relief from migraine pain.

Navigating the Desert of Migraine and Cardiovascular Risk

This research provides valuable information for healthcare providers seeking to manage migraine in patients with cardiovascular risk factors. It's a reminder that there are emerging treatment options that can offer relief without significant drawbacks.

Dr. Camel's Conclusion

This post-hoc analysis offers promising results for lasmiditan as a treatment option for acute migraine attacks in patients with cardiovascular risk factors. It represents a significant step forward in managing migraine pain in this patient population, offering a potential oasis of relief in a desert of complexities.

Date :
  1. Date Completed 2019-12-02
  2. Date Revised 2023-12-13
Further Info :

Pubmed ID

31464581

DOI: Digital Object Identifier

PMC6734241

Related Literature

Article Analysis
・Side Effects of lasmiditan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.